ADVERTISEMENT
LIVE DESK·Global markets desk·Last updated 14s ago
ADVERTISEMENT
Markets/EquitiesArticle

Heights Capital Management reaches 20.25% stake in Faron Pharmaceuticals

Heights Capital Management and its affiliate CVI Investments reported holding 20.25% of voting rights in Finnish biotech Faron Pharmaceuticals, split between 8.95% shares and 11.30% convertible bonds.

PA
Priya Anand · Equities & Earnings Desk · 8 Sept 2026 · 03:09 · 1 min read
Share
Heights Capital Management reaches 20.25% stake in Faron Pharmaceuticals

Heights Capital Management, Inc., an investment firm based in San Francisco, submitted a major holding notification to Faron Pharmaceuticals OY on September 4, 2026. The accompanying press release was issued on Sunday.

The notification shows that Heights Capital, together with its controlled undertaking CVI Investments, Inc., now holds 46,154,796 voting rights, representing 20.25% of Faron Pharmaceuticals' total voting rights.

The stake comprises 8.95% voting rights attached to shares – 20,394,796 direct rights and 25,760,000 indirect rights – and 11.30% voting rights derived from two convertible bonds. The first bond, expiring on February 8, 2027, carries 10,080,000 voting rights (4.42%), while the second bond, expiring on February 12, 2028, carries 15,680,000 voting rights (6.88%).

Previously, Heights Capital reported a 9.41% share‑based voting right and the same 11.30% from convertible bonds, for a total of 20.72% voting rights. The controlled undertaking, CVI Investments, holds identical percentages.

Heights Capital Management is not controlled by any natural person or legal entity and does not control any other undertakings holding an interest in the issuer.

This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
Novara — A Smarter Way to Access Global Markets
Share this story
PA
Written by
Priya Anand
Equities & Earnings Desk

Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.

More from Priya Anand →
ADVERTISEMENT
ADVERTISEMENT
Heights Capital hits 20.25% stake in Faron Pharma · Finance Review Daily